07:33 AM EDT, 03/26/2025 (MT Newswires) -- Alvotech ( ALVO ) , Kashiv Biosciences, and Advanz Pharma said Wednesday that the UK Medicines and Healthcare Products Regulatory Agency has accepted the marketing application for AVT23, a proposed biosimilar to Xolair.

Xolair is indicated for the treatment of severe persistent allergic asthma and chronic rhinosinusitis, the companies said.

Alvotech ( ALVO ) and Advanz Pharma have a commercialization agreement for AVT23, while Alvotech ( ALVO ) and Kashiv have a licensing agreement for AVT23, according to the statement.